Ocrevus (ocrelizumab)

Sale!
Buy Ocrevus (ocrelizumab)

$9,200.00 $7,200.00

Buy Ocrevus (ocrelizumab) at Anticancercure.com

Neurology Multiple Sclerosis
Marketing Authorisation Holder Roche Registration Limited
Mode of Action Monoclonal antibody (immunotherapy)
Administration Intravenous
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Strength 30 milligram / millilitre
Package 1 vial of 10 ml – Vials
Compare
SKU: OCEREVUS Category: Tags: ,

Description

Buy Ocrevus (ocrelizumab) at Anticancercure.com

What is Ocrevus (ocrelizumab) for?

Ocrevus (ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of people with relapsing or primary progressive forms of multiple sclerosis (MS)1,4. It is the first approved treatment for the primary progressive form of MS2.

Relapsing MS (RMS) is characterized by episodes of worsening function (relapses) which are initially followed by recovery periods (remissions). In its primary progressive form (PPMS), MS is characterized by steadily worsening function from the onset of symptoms, often without early relapses or remissions2.

How does Ocrevus (ocrelizumab) work?

MS is a chronic, inflammatory, autoimmune disease that affects the central nervous system, and in particular the communication between the brain and other parts of the body2. The patient’s own immune system is supposed to be the cause of the damage to neurons3.

The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to bind to a type of antigen, named CD20, found on the surface of some antibodies (pre-B and mature B lymphocytes) and induce their death2. In this way, it is supposed to prevent these antibodies from damaging neurons.

Where has Ocrevus (ocrelizumab) been approved?

Ocrevus (ocrelizumab) was approved for relapsing or primary progressive forms of multiple sclerosis (MS) by:

  • Food and Drug Administration (FDA), USA, March 28, 20171
  • European Medical Agency (EMA), European Union, January 11, 20175
  • Therapeutic Goods Administration (TGA), Australia, July 13, 20174

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Ocrevus (ocrelizumab) taken?

The standard dosage is1,4,5:

  • Starting dose of 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion
  • Subsequent doses of 600 mg intravenous infusion every 6 months.

Patients should be monitored closely during and for at least one hour after infusion as infusion reactions may be possible.

Complete information about Ocrevus (ocrelizumab) dosage and administration can be found in the official prescribing information listed in our resources section1,4,5.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Ocrevus (ocrelizumab)?

Common adverse reactions

Relapsing MS

The most common adverse reactions listed in the prescribing information include1,4,5:

  • upper respiratory tract infections
  • infusion reactions.

Primary progressive MS

The most common adverse reactions listed in the prescribing information include1,4,5:

  • upper respiratory tract infections
  • infusion reactions
  • skin infections
  • lower respiratory tract infections.

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include1,4,5:

  • serious infusion reactions requiring hospitalisation
  • infections: administration should be delayed in patients with an active infection until the infection is resolved.
  • an increased risk of malignancy, including breast cancer, may exist.

Use in a specific population

Ocrevus (ocrelizumab) can cause fetal harm, it is advised to avoid pregnancies1 unless the potential benefit to the mother outweighs the potential risk to the foetus4,5. It is unknown whether ocrelizumab/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Women should be advised to discontinue breastfeeding during Ocrevus (ocrelizumab) therapy1,4,5.

Patients in a severely immunocompromised state must not be treated until the condition resolves1,4,5.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,4,5.

 

Follow the following prescription medicine precautions :

    Ocrelizumab may be harmful in pregnancy and there is a potential risk of miscarriage or carrying a child with birth defects if you or your partner becomes pregnant during this time. Take proper medical help in case you are pregnant, may be pregnant or planning to become pregnant in the near future.
  This medicine is not indicated for use in women. It is not known if  Ocrelizumab is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Ocrelizumab, a decision should be made to either discontinue nursing, or discontinue the drug taking into account the importance of the drug to the mother.
  Your health care professional may recommend blood tests to see how your body is working. Blood tests help doctors check for certain diseases and conditions. They also help check the function of your organs and show how well treatments are working.
  Before taking Ocrelizumab, tell your doctor and pharmacist if you are allergic to Ocrelizumab, any other medications, or any of the ingredients in Ocrelizumab injection. This medicine is not recommended for use in patients with a known allergy to Ocrelizumab.
  If you take Ocrelizumab, you must stop drinking alcohol. This is one of the ways to prevent this disease from getting worse. If you are dependent on alcohol and want to stop drinking, your doctor can recommend a therapy that’s tailored for your needs.
  If you use other prescription drugs or over the counter products at the same time, the effects of Ocrelizumab may change. Tell your doctor about all the drugs, vitamins, and herbal supplements you are using, so that your pharmacist can help you prevent or manage drug interactions.
  Missing a dose of Ocrelizumab can upset your treatment plan. If you do miss one of your doses, take it as soon as you remember, unless it’s almost time to take your next dose. In this case, you should just skip the missed dose. Don’t take a double dose to “make up” for the one you missed. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
  Do not take Ocrelizumab the use by (expiry) date printed on the pack. Do not take it if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.
  During your treatment with Ocrelizumab, it is very important for your doctor to know about your medical history if you have Kidney problems, liver problems, HIV, triglycerides, diabetes or other health problems.

 

What are the storage instructions for Ocrelizumab 30mg/L mg ?

Patients must properly store the drug to retain its quality and efficacy. Following storage instructions will be helpful in storing the drug in the best of manner. 

  • Store Ocrelizumab 30mg/L at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
  • Store it in a cool, dry place, protected from light and refrigerated when necessary. Improper storage can affect the effectiveness and shelf life of your medicine.
  • Consider storing your medications separately from your other family members. You can put them on a different shelf, or in a different cabinet or drawer.
  • If you’re driving, you may want to have certain medicines at hand, but don’t store them in the glove compartment, where they could be damaged from the heat, cold, or rain outside or from the car’s heater or air conditioner.
  • Always remember to store your medication out of sight and reach of children and pets, to prevent accidental ingestion.

Prescription Required:

anticancercure.com is one of the leading suppliers of Ocrelizumab 30mg/L and has won the trust of thousands of customers by delivering Ocrelizumab 30mg/L cancer medicine at the lowest price globally. If you want to buy Ocrelizumab 30mg/L injection, place your order online and get them delivered at your doorsteps within the specified time-frame.

We Ship in – USA, UK, China, Canada, Russia, Australia, UAE, Singapore, Philippines, Bulgaria, Hungary, Italy, Kenya, Nigeria, Saudi Arabia, Taiwan, Zimbabwe, Malaysia, Spain, Hong Kong and many other countries.

In order to legally purchase this medicine from anticancercure.com , you’ll require a prescription from your Registered Medical Practitioner.

Note:

The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Remember, keep this and all other medicines out of the reach of children and away from pets, never share your medicines with others, and use this medication only for the indication prescribed.

The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Ocrevus (ocrelizumab)

Reviews

There are no reviews yet.

Be the first to review “Ocrevus (ocrelizumab)”
Scroll to top
Translate »
Have no product in the cart!
0